Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Total Non-Current Liabilities: 2019-2025

Historic Total Non-Current Liabilities for Pharming Group N.V (PHAR) over the last 5 years, with Sep 2025 value amounting to $121.2 million.

  • Pharming Group N.V's Total Non-Current Liabilities rose 1.12% to $121.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.2 million, marking a year-over-year increase of 1.12%. This contributed to the annual value of $105.1 million for FY2024, which is 36.71% down from last year.
  • Per Pharming Group N.V's latest filing, its Total Non-Current Liabilities stood at $121.2 million for Q3 2025, which was up 2.07% from $118.8 million recorded in Q2 2025.
  • Pharming Group N.V's 5-year Total Non-Current Liabilities high stood at $166.1 million for Q4 2023, and its period low was $135,375 during Q3 2022.
  • Its 3-year average for Total Non-Current Liabilities is $124.8 million, with a median of $119.9 million in 2024.
  • As far as peak fluctuations go, Pharming Group N.V's Total Non-Current Liabilities crashed by 99.92% in 2022, and later soared by 116,957.80% in 2023.
  • Quarterly analysis of 5 years shows Pharming Group N.V's Total Non-Current Liabilities stood at $157.6 million in 2021, then grew by 2.43% to $161.5 million in 2022, then rose by 2.88% to $166.1 million in 2023, then plummeted by 36.71% to $105.1 million in 2024, then rose by 1.12% to $121.2 million in 2025.
  • Its Total Non-Current Liabilities stands at $121.2 million for Q3 2025, versus $118.8 million for Q2 2025 and $110.4 million for Q1 2025.